MFGR1877S

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

Multiple MyelomaSolid Tumor

Phase 1

A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

CompletedNCT01122875

Genentech, Inc.Multiple Myeloma

Start: 2010-11-30End: 2012-05-31Updated: 2016-11-02

Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors

CompletedNCT01363024

Genentech, Inc.Solid Tumor

Start: 2011-08-31End: 2013-03-31Updated: 2016-11-02